PixarBio Corporation (“PixarBio” or “the Company”), a biotechnology company developing a morphine replacement, non-opiate, non-addictive post-surgical pain treatment, today announced that its Chief Executive Officer, Mr. Frank M. Reynolds, will be participating in a discussion panel addressing the opioid and heroin epidemic facing the State of Connecticut titled “The Face of Addiction: A Conversation on Connecticut’s Opioid Addiction” hosted by the Nantucket Project.
“The abuse and addiction to opioids is a serious global health problem that is having devastating effects on communities all around the world, and I am glad to call further attention to this problem in today’s event in Connecticut,” commented Frank M. Reynolds, CEO of PixarBio, “It is precisely because of the trauma and tragedy of opiate addiction that PixarBio is developing a novel product, NeuroRelease™, that is designed to eradicate the need for post-surgical use of opioid-based prescription pain relievers that are currently in widespread use for the treatment of acute and chronic pain. I am pleased to join an esteemed panel in addressing this very serious problem and to be a part of the solution, to solving this epidemic.”
The event information is as follows:
|Date:||Tuesday, August 30, 2016|
7:00 PM – 8:30 PM
|Location:||The Nantucket Project|
|123 Mason Street|
About The Nantucket Project
The Nantucket Project is an annual gathering that takes place in Nantucket, Massachusetts, that celebrates the richness of the human experience through storytelling. Its speakers explore the human imagination, creativity, thought-leadership, business values, and social change. Its goal is to exchange challenging ideas, build strong relationships and share ground-breaking insights that build a better tomorrow and unlock the power of human potential. Additional information can be found at https://www.nantucketproject.com/nantucket-project.
About PixarBio Corporation
Cofounded by Frank M. Reynolds, MIT’s Dr. Robert S. Langer, Katrin Holzhaus, Dr. Jason Criscione, Haining Dai, Xi Chen, and Dr. Amer Khalil. PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For more information, visit www.pixarbio.com.
Safe Harbor Statement
This announcement includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of PixarBio’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of Biotech and medical device industry regulation and health care legislation in the United States and internationally; global trends on cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; PixarBio’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of PixarBio’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
PixarBio Corp undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be obtained through PixarBio’s Corp HQ at 200 Boston Ave, Suite 1875 in Medford, MA 02155. PixarBio Corp is a private corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160830005355/en/Business Wire
Last updated on: 30/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.